Publications

BibTex format

@article{Fendler:2022:10.1016/j.xcrm.2022.100781,
author = {Fendler, A and Shepherd, STC and Au, L and Wu, M and Harvey, R and Wilkinson, KA and Schmitt, AM and Tippu, Z and Shum, B and Farag, S and Rogiers, A and Carlyle, E and Edmonds, K and Del, Rosario L and Lingard, K and Mangwende, M and Holt, L and Ahmod, H and Korteweg, J and Foley, T and Barber, T and Emslie-Henry, A and Caulfield-Lynch, N and Byrne, F and Deng, D and Kjaer, S and Song, O-R and Queval, CJ and Kavanagh, C and Wall, EC and Carr, EJ and Caidan, S and Gavrielides, M and MacRae, JI and Kelly, G and Peat, K and Kelly, D and Murra, A and Kelly, K and O'Flaherty, M and Shea, RL and Gardner, G and Murray, D and Popat, S and Yousaf, N and Jhanji, S and Tatham, K and Cunningham, D and Van, As N and Young, K and Furness, AJS and Pickering, L and Beale, R and Swanton, C and Gandhi, S and Gamblin, S and Bauer, DLV and Kassiotis, G and Howell, M and Nicholson, E and Walker, S and Wilkinson, RJ and Larkin, J and Turajlic, S},
doi = {10.1016/j.xcrm.2022.100781},
journal = {Cell Reports Medicine},
title = {Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer},
url = {http://dx.doi.org/10.1016/j.xcrm.2022.100781},
volume = {3},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titers and T cell responses after the fourth vaccine dose increased compared with that after the third vaccine dose. Patients who received B cell-depleting therapies within the 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination.
AU  - Fendler,A
AU  - Shepherd,STC
AU  - Au,L
AU  - Wu,M
AU  - Harvey,R
AU  - Wilkinson,KA
AU  - Schmitt,AM
AU  - Tippu,Z
AU  - Shum,B
AU  - Farag,S
AU  - Rogiers,A
AU  - Carlyle,E
AU  - Edmonds,K
AU  - Del,Rosario L
AU  - Lingard,K
AU  - Mangwende,M
AU  - Holt,L
AU  - Ahmod,H
AU  - Korteweg,J
AU  - Foley,T
AU  - Barber,T
AU  - Emslie-Henry,A
AU  - Caulfield-Lynch,N
AU  - Byrne,F
AU  - Deng,D
AU  - Kjaer,S
AU  - Song,O-R
AU  - Queval,CJ
AU  - Kavanagh,C
AU  - Wall,EC
AU  - Carr,EJ
AU  - Caidan,S
AU  - Gavrielides,M
AU  - MacRae,JI
AU  - Kelly,G
AU  - Peat,K
AU  - Kelly,D
AU  - Murra,A
AU  - Kelly,K
AU  - O'Flaherty,M
AU  - Shea,RL
AU  - Gardner,G
AU  - Murray,D
AU  - Popat,S
AU  - Yousaf,N
AU  - Jhanji,S
AU  - Tatham,K
AU  - Cunningham,D
AU  - Van,As N
AU  - Young,K
AU  - Furness,AJS
AU  - Pickering,L
AU  - Beale,R
AU  - Swanton,C
AU  - Gandhi,S
AU  - Gamblin,S
AU  - Bauer,DLV
AU  - Kassiotis,G
AU  - Howell,M
AU  - Nicholson,E
AU  - Walker,S
AU  - Wilkinson,RJ
AU  - Larkin,J
AU  - Turajlic,S
DO  - 10.1016/j.xcrm.2022.100781
PY  - 2022///
SN  - 2666-3791
TI  - Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer
T2  - Cell Reports Medicine
UR  - http://dx.doi.org/10.1016/j.xcrm.2022.100781
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36240755
UR  - http://hdl.handle.net/10044/1/100188
VL  - 3
ER  -

Download

DrSanjayPopat

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)